Search results
Results from the WOW.Com Content Network
Simvastatin was initially marketed by Merck & Co under the brand name Zocor but is available generically in most countries following the patent expiry. [citation needed] A combination of simvastatin along with ezetimibe is sold under the brand name Vytorin and is jointly marketed by Merck and Schering-Plough. [citation needed]
The combination preparation is marketed by Merck & Co. under the trade names Vytorin in the US and Inegy in the European Union. In 2018, it was the 349th most commonly prescribed medication in the United States, with more than 800 thousand prescriptions.
Patent Application Information Retrieval (PAIR) is an online service provided by the United States Patent and Trademark Office to allow users to see the prosecution histories of United States patents and patent applications and obtain copies of documents filed therein. There are two services: Public PAIR, which allows the general public to ...
PATENTSCOPE is a global patent database and search system developed and maintained by the World Intellectual Property Organization. It provides free and open access to a vast collection of international patent documents, including patent applications , granted patents, and related technical information.
Wikipedia entry for Google Patents.Google Patents is a search engine from Google that indexes patents and patent applications from the United States Patent and Trademark Office.
Since 2010, numerous pharmaceutical board busters have started to become off-patent. [34] As seen in the figure below, the top five off-patent proprietary drug before 2017 have a combined lifetime sale of around US$588.4 Billion, [35] which is enormous enough to surpass the bottom 5% countries' GDP in 2020. [36]
It was covered by U.S. Patent no. 4997841; the FDA lists the patent as expiring on July 7, 2010. [8] [9] In July 2010, in the wake of the patent expiration, several drug manufacturers, including Roxane Labs, [10] Sandoz [11] and Teva Pharmaceuticals, [12] announced that they were launching generic Naratriptan medications.
the maximum duration of market exclusivity (patent + SPC) can now be up to at least 15.5 years. An extension of an SPC can only be awarded if there is an SPC to extend. As an unextended SPC only has a positive term if more than 5 years have elapsed between patent filing and MA issuance, this leads to the following two questions.